The WHO's REACT Working Group published an analysis of seven trials of dexamethasone, hydrocortisone and methylprednisolone in the Journal of the American Medical Association Wednesday, finding a lower rate of all-cause mortality at 28 days among critically ill patients receiving the drugs.
The FDA has given the green light to Emflaza (deflazacort), a new drug for Duchenne muscular dystrophy. Announced Thursday, the news is bittersweet. Deflazacort is a corticosteroid, a class of drugs that doctors have used off-label for many years.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Sparrow Pharmaceuticals won the therapeutics category as part of this year’s Best of INVEST awards. Corticosteroids are an important anti-inflammatory treatment agent for a variety of medical conditions – ranging from autoimmune to cancer to organ transplants. However, chronic use of these drugs can lead to a similarly wide range of side effects. Sparrow Pharmaceuticals has brushed the dust […]